The Michael J. Fox Foundation for Parkinson’s Research & The New York Academy of Sciences
Parkinson’s Disease Therapeutics Conference
New York, NY
October 24, 2013

Poster Session on Novel Therapeutic Targets and Tools

Marco Baptista, PhD, The Michael J. Fox Foundation - “LRRK2 Knockout Rat Characterization: Histopathology and Clinical Chemistry”

Benjamin S. Bleier, MD, Harvard Medical School and The Massachusetts Eye and Ear Infirmary - “Non-Invasive Striatal Delivery of Glial Derived Neurotrophic Factor (GDNF) via a Novel Heterotopic Mucosal Grafting Technique”

Neal F. Kassell, MD, Focused Ultrasound Foundation and University of Virginia - “A Feasibility Study to Evaluate Safety and Initial Effectiveness of Magnetic Resonance Guided Focused Ultrasound for Unilateral Pallidotomy in the Treatment of Dyskinesia of Parkinson’s Disease”

Wassilios Meissner, MD, PhD, CHU Bordeaux and Institut des Maladies Neurodégénératives, Université Bordeaux Ségalen, CNRS UMR 5293, Bordeaux, France - “Coordinated Reset (CR) Neuromodulation of the Subthalamic Nucleus in the MPTP Non-Human Primate Model: Target Validation for Translating into a Clinical Trial in Parkinson’s Disease Patients”

Nadav Navon, PhD, MBA, Intec Pharma Ltd. - “Accordion Pill Carbidopa – Levodopa (AP CD/LD) for Improved Treatment of Parkinson's Disease - 180 Days Oral Toxicity Study in Mini-Pigs, Towards Phase III Study”

Thomas A. Rooney, PhD, Sanofi - “Pharmacological Testing of Nurr1 Agonists in Animal Models of Parkinson's Disease”

Stephan Schann, PhD, Domain Therapeutics - “mGluR3 PAM: a Novel Neuroprotective Strategy for Parkinson's Disease”

Malú G. Tansey, PhD, Emory University School of Medicine - “Peripheral Administration of XPro1595, a Selective Inhibitor of Soluble TNF, in the Pre-clinical 6-OHDA Model of Parkinson's Disease”

Kendall Van Keuren-Jensen, PhD, The Translational Genomics Research Institute - “MicroRNAs as Biomarkers for Parkinson's Disease; a Comparison of Cerebrospinal Fluid and Blood”

Andrew West, PhD, University of Alabama at Birmingham - “Role of LRRK2 in Alpha-Synuclein-Induced Neurodegeneration”